<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913328</url>
  </required_header>
  <id_info>
    <org_study_id>SINGDEN-04-2002</org_study_id>
    <nct_id>NCT00913328</nct_id>
  </id_info>
  <brief_title>Effect of Add-on Montelukast to Inhaled Corticosteroids on Airway Responsiveness</brief_title>
  <acronym>SINGDEN</acronym>
  <official_title>Effect of Add-on Montelukast to Inhaled Corticosteroids in Excessive Airway Narrowing in Adults With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leukotriene receptor antagonists appear to posses additive anti-inflammatory effects to the
      effect of inhaled corticosteroids.

      Hypothesis: Treatment with oral montelukast will lower the dose-response plateau to inhaled
      methacholine in patients with mild to moderate persistent asthma treated with a stable dose
      of inhaled corticosteroids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in maximal FEV1 decline at the dose-response plateau</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in PD20 methacholine</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral montelukast 10 mg once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast (Singulair)</intervention_name>
    <description>10 mg tablet once daily</description>
    <arm_group_label>Montelukast</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking adults with mild to moderate persistent asthma:

               -  FEV1 &gt; 70 % pred

               -  PD20 methacholine &lt; 3.9 mmol

               -  treated for at least 3 months with a stable dose of inhaled corticosteroids

          -  Documented dose-response plateau to inhaled methacholine on two occasions

          -  Males and non-pregnant females

        Exclusion Criteria:

          -  Asthma medication other than inhaled corticosteroids and inhaled b2-agonists

          -  Viral respiratory tract infections within the 3 weeks prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zuzana Diamant, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlotte S Ulrik, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Heart and Lung Diseases, Hvidovre Hospital, Denmark</affiliation>
  </overall_official>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>June 3, 2009</last_update_submitted>
  <last_update_submitted_qc>June 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ass. prof. of Medicine Charlotte Suppli Ulrik</name_title>
    <organization>Department of Heart and Lung Diseases, Hvidovre Hospital</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Airway responsiveness</keyword>
  <keyword>Dose-response plateau</keyword>
  <keyword>Montelukast</keyword>
  <keyword>Add-on to inhaled corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

